Atopic Dermatitis in Elderly Patients: Discussing the Safety of Lebrikizumab in an 86-Year-Old Patient.

Overview

In this video, Dr. Naiem T. Issa reviews the established safety profile of Ebglyss®
(lebrikizumab), including key safety considerations, common adverse events, and its use
without routine lab monitoring or dose adjustments. He also presents a real-world case of
an 86-year-old patient with severe atopic dermatitis, demonstrating rapid improvements in
BSA and itch severity within just 2 weeks of treatment, highlighting the safety and fast
efficacy of lebrikizumab in elderly patients.

This Class for

• Clinical Pharmacy
• Pharmacy
• Physician
• Resident / Fellow

What I will learn?

• ● Review the established safety profile of lebrikizumab in adults and adolescents.
  ● Highlight key safety considerations, including no routine lab monitoring and no dose adjustments by age or weight.
  ● Summarize common adverse events reported in clinical trials.
  ● Demonstrate the rapid efficacy and safety of lebrikizumab through a real-world case in an elderly patient with comorbidities.

Related Classes

• Key IL-13 Skin and Itch Data in Moderate-to-Severe AD.
• Atopic Dermatitis in Visible Areas Is a Real Challenge!
• Depth of Response & Stability of Response of Lebrikizumab
• Can You Reach EASI Targets Faster? – AD Case with Prof. Naiem Issa
• Deep Response to IL‑13 and IL‑4/13 Inhibition in AD
• Role of IL‑13 in Atopic Dermatitis (AD)
• Is FACE/Neck AD Treatable? A Real Patient Case with Dr. Fares Alkhayal
• Ebglyss Monthly Maintenance Dosing.Simply No lab monitoring , No boxed warning & No dose adjustment